Cellonis Biotechnology Co. Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (2004)

Organization Overview

First Clinical Trial
2010
NCT01142050
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Infarction (Phase 2)

Infarction, Middle Cerebral Artery (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4